Spero Therapeutics announced that Dr. Patrick Vink resigned and Dr. William Ho will join the Board on November 10, 2026.

Nov 10, 2026, 5:33 PM ETNew bossRead the original at SEC EDGAR

Neutral

Spero replaced a departing director with a biotech executive who has more than 20 years of clinical development experience. The departure was not tied to a dispute, and the filing reports no change to company programs, so the board update does not change Spero's outlook.

SPRO · Spero Therapeutics, Inc.

AI read · Neutral

The AI's read

Dr. Ho's experience could help Spero oversee drug development. The filing reports no disagreement behind Dr. Vink's departure and no change to Spero's programs. Dr. Ho will receive cash payments and an option for 100,000 shares. The filing does not show how these board changes would alter Spero's business outlook.

Get alerts for SPRO

Follow Spero Therapeutics, Inc. (SPRO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SPRO

Free on the App Store and Google Play, or on the web.